Guardant Health, Inc. (GH)Healthcare | Diagnostics & Research | Palo Alto, United States | NasdaqGS
165.88 USD
+2.89
(1.773%)
⇧
(Oct. 15, 2026, 4 p.m.
EDT)
After hours: 165.12 -0.76 (-0.759%) ⇩ (Oct. 15, 2026, 7:02 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 2:49 a.m. EDT
The investment case hinges on robust revenue growth offsetting persistent financial losses. The long-term rating is constrained by the absence of sufficient price history to validate the market's assessment of business quality, alongside negative earnings and equity. Short-term momentum is constructive, with the stock trading near its yearly high and options speculators positioning for upside moves above 180, though heavy put volume at lower strikes suggests a floor around 150. Analyst consensus is bullish, but the lack of profitability and missing price trajectory prevent a higher conviction rating. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.052860 |
| MSTL | 0.142719 |
| AutoETS | 0.143167 |
| AutoARIMA | 0.144632 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 44% |
| H-stat | 0.38 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.751 |
| Excess Kurtosis | -0.44 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 9.142 |
| Market Cap | 22,260,461,568 |
| Forward P/E | -405.92 |
| Beta | 1.58 |
| Profit Margins | -38.33% |
| Website | https://guardanthealth.com |
As of Oct. 10, 2026, 2:49 a.m. EDT: Implied volatility is elevated across expirations, indicating uncertainty. Call open interest builds significantly at 180, 190, and 200 strikes, suggesting bullish positioning for upside beyond current levels. Conversely, put open interest concentrates heavily at 150 and 160 strikes, establishing a defensive floor. The imbalance favors a range-bound scenario with a bullish bias toward the upper end of the 150-200 corridor.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.4157403 |
| Address1 | 3,100 Hanover Street |
| All Time High | 191.05 |
| All Time Low | 15.81 |
| Ask | 174.92 |
| Ask Size | 2 |
| Audit Risk | 1 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 1,818,850 |
| Average Daily Volume3 Month | 1,965,206 |
| Average Volume | 1,965,206 |
| Average Volume10Days | 1,818,850 |
| Beta | 1.583 |
| Bid | 163.4 |
| Bid Size | 1 |
| Board Risk | 7 |
| Book Value | -1.668 |
| City | Palo Alto |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 165.88 |
| Current Ratio | 4.026 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 168.86 |
| Day Low | 158.998 |
| Display Name | Guardant Health |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,793,908,800 |
| Earnings Call Timestamp Start | 1,793,908,800 |
| Earnings Timestamp | 1,793,908,800 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -430,571,008 |
| Ebitda Margins | -0.36393002 |
| Enterprise To Ebitda | -53.194 |
| Enterprise To Revenue | 19.359 |
| Enterprise Value | 22,904,004,608 |
| Eps Current Year | -1.4622 |
| Eps Forward | -0.40865 |
| Eps Trailing Twelve Months | -3.58 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 888 974 4258 |
| Fifty Day Average | 168.0054 |
| Fifty Day Average Change | -2.1253967 |
| Fifty Day Average Change Percent | -0.012650765 |
| Fifty Two Week Change Percent | 141.57402 |
| Fifty Two Week High | 191.05 |
| Fifty Two Week High Change | -25.169998 |
| Fifty Two Week High Change Percent | -0.1317456 |
| Fifty Two Week Low | 64.0 |
| Fifty Two Week Low Change | 101.880005 |
| Fifty Two Week Low Change Percent | 1.5918751 |
| Fifty Two Week Range | 64.0 - 191.05 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,538,659,800,000 |
| Float Shares | 129,479,175 |
| Forward Eps | -0.40865 |
| Forward P E | -405.92194 |
| Free Cashflow | 26,607,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 2,490 |
| Fullday Change | 2.1306 |
| Fullday Change Percent | 1.3071967 |
| Fullday Price | 165.88 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.65012 |
| Gross Profits | 769,158,016 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03977 |
| Held Percent Institutions | 1.0097799 |
| Implied Shares Outstanding | 134,196,170 |
| Industry | Diagnostics & Research |
| Industry Disp | Diagnostics & Research |
| Industry Key | diagnostics-research |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California. |
| Long Name | Guardant Health, Inc. |
| Market | us_market |
| Market Cap | 22,260,461,568 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_256906841 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -453,436,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 23,774,193,477 |
| Number Of Analyst Opinions | 25 |
| Open | 160.78 |
| Operating Cashflow | -185,187,008 |
| Operating Margins | -0.38247 |
| Overall Risk | 6 |
| Phone | 855 698 8887 |
| Post Market Change | -0.7593994 |
| Post Market Change Percent | -0.45780045 |
| Post Market Price | 165.1206 |
| Post Market Time | 1,792,105,372 |
| Previous Close | 162.99 |
| Price Eps Current Year | -113.445496 |
| Price Hint | 2 |
| Price To Book | -99.44845 |
| Price To Sales Trailing12 Months | 18.815289 |
| Profit Margins | -0.38326 |
| Quick Ratio | 3.533 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.30769 |
| Region | US |
| Regular Market Change | 2.89 |
| Regular Market Change Percent | 1.77311 |
| Regular Market Day High | 168.86 |
| Regular Market Day Low | 158.998 |
| Regular Market Day Range | 158.998 - 168.86 |
| Regular Market Open | 160.78 |
| Regular Market Previous Close | 162.99 |
| Regular Market Price | 165.88 |
| Regular Market Time | 1,792,094,401 |
| Regular Market Volume | 1,322,290 |
| Return On Assets | -0.18070999 |
| Revenue Growth | 0.443 |
| Revenue Per Share | 9.142 |
| Sand P52 Week Change | 0.16440773 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 134,196,170 |
| Shares Percent Shares Out | 0.0888 |
| Shares Short | 11,915,002 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 11,050,208 |
| Short Name | Guardant Health, Inc. |
| Short Percent Of Float | 0.0925 |
| Short Ratio | 6.5 |
| Source Interval | 15 |
| State | CA |
| Symbol | GH |
| Target High Price | 240.0 |
| Target Low Price | 105.0 |
| Target Mean Price | 201.64 |
| Target Median Price | 200.0 |
| Total Cash | 1,053,468,992 |
| Total Cash Per Share | 7.85 |
| Total Debt | 1,697,012,992 |
| Total Revenue | 1,183,105,024 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.58 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 126.64885 |
| Two Hundred Day Average Change | 39.231155 |
| Two Hundred Day Average Change Percent | 0.30976322 |
| Type Disp | Equity |
| Volume | 1,322,290 |
| Website | https://guardanthealth.com |
| Zip | 94,304 |